Skip to content

The Relax Study: investigation of adjuvant Botox injection in the surgical repair of complicated perianal fistula disease

Investigation into the feasibility of adjuvant botulinum toxin injection in the surgical repair of complicated perianal fistula disease – a multicentred, participant blinded study with Patient Reported Outcome Measures and quantitative clinical outcomes. The Relax Study: investigation of adjuvant Botox injection in the surgical repair of complicated perianal fistula disease.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625001347459
Acronym
RELAX
Enrollment
20
Registered
2025-12-02
Start date
2026-08-01
Completion date
2026-12-31
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The Relax Study will test whether Botox injection into the anal sphinceters and pelvic floor during standard surgery can improve healing and symptoms for people with complex perianal fistula. Botox briefly relaxes the anal muscles, which may support recovery. Participants will receive surgery with or without Botox and will report on their symptoms afterward. We hypothesize that Botox will lead to better symptom improvement and healing at three months.

Interventions

All participants will complete a baseline PROCTOPROM questionnaire and undergo routine clinical and radiological assessment to classify their disease as a part of their operative planning. During surgery, the modality of sphincter sparing surgery will remain as per the surgeon’s choice for all participants. Alongside surgery, the intervention group will receive a total of 100U Botox reconstituted into 1ml of saline. This will be injected as 50IU into puborectalis and 50IU in the intersphincter

All participants will complete a baseline PROCTOPROM questionnaire and undergo routine clinical and radiological assessment to classify their disease as a part of their operative planning. During surgery, the modality of sphincter sparing surgery will remain as per the surgeon’s choice for all participants. Alongside surgery, the intervention group will receive a total of 100U Botox reconstituted into 1ml of saline. This will be injected as 50IU into puborectalis and 50IU in the intersphincteric plane, under the guidance of a consultant surgeon with expert understanding of the regional anatomy. The use and the method will be recorrected in the operation note. Post operative intervention will remain at the surgeon’s discretion for both the control and intervention arms. At 3 months (as per established departmental protocol), the participant will be assessed by an extended PROCTOPROM and outpatient clinical assessment.

Sponsors

Queen Elzabeth II Jubilee Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• All consenting adults over the age of 18 years who have a perianal fistula that are put forward for sphincter sparing surgery. • Participants may have had previous attempts of repair.

Exclusion criteria

• Those who are unwilling or not able to complete the PROCTOPROM questionnaire despite appropriate help. • Aetiology due to Inflammatory Bowel Disease, Hidradenitis suppurative or malignancy. • Anorectal-vaginal fistulae. • Immunosuppressed. • Known collagen or generalised musculoskeletal disease. • Known adverse events from Botox (including hypersensitivity, myasthenia gravis and Eaton Lambert Syndrome.) • Those who do not consent to participate.

Outcome results

None listed

Source: ANZCTR · Data processed: Jul 23, 2026